|
Elected to our Board in May 2006, John E. Crawford serves as an independent director and his previous experience qualifies him as a financial expert. He is Chairman of the Audit Committee, and a member of the Nominating and Corporate Governance and Compensation Committees of the Board.
Mr. Crawford has extensive experience in the areas of biopharmaceuticals and medical devices. Until September 2007, he was the Chief Financial Officer of NovaCardia, a privately-held, specialty pharmaceutical company with significant capabilities and experience in cardiovascular drug development. When it was recently acquired by Merck & Co., Inc., NovaCardia had, in late-stage clinical trials, a compound for the treatment of congestive heart failure. Previously, Mr. Crawford was the Chief Financial and Administrative Officer of Cabrellis Pharmaceuticals Corporation, a specialty-pharmaceuticals company focused on cancer therapy. Pharmion purchased Cabrellis in November 2006.
Mr. Crawford was the founding president of Corvas International, Inc., a biopharmaceutical company which focused on therapeutic agents for the prevention and treatment of major cardiovascular and inflammatory diseases. While at Corvas he held a variety of senior management positions and raised over $200 million in equity and research funding during his tenure as Chief Financial Officer. He also served as Chief Financial Officer at Conforma Therapeutics Corp., a privately-held biopharmaceuticals company focused on cancer. In May 2006, Conforma Therapeutics merged with Biogen Idec.
Mr. Crawford received his bachelor's degree in mathematical sciences from Stanford University, and his MBA from the University of Chicago Graduate School of Business. | 